The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

• Status: Completed
• Trial end date: 2010-07-09
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to see if the blood pressure and metabolic effects of an approved drug nebivolol is comparable to that of another approved drug hydrochlorothiazide (HCTZ) and placebo in hypertensive patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories
• Treatments: Hydrochlorothiazide; Lisinopril; Losartan; Nebivolol

Criteria

Inclusion Criteria:

• Male or female, ambulatory outpatients 18-80 years old at screening.

• Have a history of hypertension and taking up to 2 medications for high blood pressure.

• Qualifying laboratory results confirming impaired fasting glucose or impaired glucose tolerance

• Vision and hearing (hearing aid permissible) sufficient for compliance with questionnaire completion

Exclusion Criteria:

• Have clinically significant respiratory, liver or cardiovascular disease

• Presence of coronary artery disease requiring treatment with a beat blocker, calcium channel blocker or nitrates

• Use of niacin or antidiabetic drugs (oral or injectable) within 6 months before study entry

• Have a history of hypersensitivity to nebivolol, other beta-blockers, hydrochlorothiazide, or other sulfonamide-derived drugs.